Kinea Bio Inc.
Mukilteo, WA
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 12600 Hummingbird St, Mukilteo, WA 98275, USA
- Website
- kineabio.com
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Greenstone Biosciences, Inc. | Palo Alto, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Cure Rare Disease | Woodbridge, CT | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Myogene Bio LLC | San Diego, CA | — |
| Phoenix Nest Inc. | NY | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Emmune Inc. | Cambridge, MA | — |
About the company
Kinea Bio Inc., a for-profit biotech company based in Mukilteo, Washington, is a federal grant recipient (100% of recent awards) conducting gene therapy research and development for muscular dystrophy and related genetic disorders under National Institutes of Health funding.
Kinea Bio's recent federal footprint consists entirely of SBIR and Project Grant awards from two NIH institutes, totaling $906,528 in combined obligated dollars across three awards spanning September 2024 through September 2026. The vendor's customer base splits evenly between the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS, two awards) and the National Heart, Lung, and Blood Institute (NHLBI, one award). The NIAMS awards include a $306,859 SBIR Phase 1 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), awarded September 15, 2025, to develop scalable non-viral gene delivery using cell-derived nanovesicles for myotonic dystrophy type 1, with completion targeted for August 31, 2026; and a $599,669 Project Grant awarded September 19, 2024, for development of novel genetic medicine approaches to treat orphan diseases, extending through May 31, 2027. The NHLBI award, a $599,669 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837), was issued September 1, 2026, to develop and validate KNA-123, an innovative gene therapy for Duchenne muscular dystrophy targeting cardiac muscle degeneration using the split intein-mediated protein ligation for gene therapy (SIMPLI-GT) platform, with performance through August 31, 2027.
Kinea Bio operates as a prime recipient across all three awards. Two awards reach completion within the next twenty-four months, creating a recompete window for the vendor as NIH cycle planning advances. The vendor's capability portfolio centers on dual AAV vector delivery platforms, split-intein protein ligation technology for overcoming AAV cargo capacity limitations, and preclinical validation of gene therapies in iPSC-derived patient models and animal models of muscular dystrophy.
SBA capabilities narrative
Kinea Bio provides research and development services in therapeutics discovery and development for musculoskeletal, neuromuscular, and cardiovascular indications, leveraging proprietary technology platforms including in vitro stem cell based assays and customizable regulatory cassettes for genetic medicines.
Quick answers
Is Kinea Bio Inc. registered in SAM.gov?
Yes. Kinea Bio Inc.'s SAM.gov registration is active through January 6, 2027.
What is Kinea Bio Inc.'s CAGE code?
Kinea Bio Inc.'s CAGE code is 8Q031, and its Unique Entity ID (UEI) is HMHJT133QNH1.
What is Kinea Bio Inc.'s most recent federal award?
Kinea Bio Inc.'s most recent federal grant award is Split-intein protein ligation: enabling AAV delivery of large genes for clinical translation in genetic cardiac diseases (R44HL182563), from National Heart Lung and Blood Institute (NIH), on September 1, 2026.
On GovTribe
See Kinea Bio Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors